Cost-Effectiveness of Nilotinib Versus Dasatinib for The Second-Line Treatment of Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Resistant or Intolerant To Imatinib, in Frame of Russian He ...
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.247
https://www.valueinhealthjournal.com/article/S1098-3015(17)30581-8/fulltext
Title :
Cost-Effectiveness of Nilotinib Versus Dasatinib for The Second-Line Treatment of Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Resistant or Intolerant To Imatinib, in Frame of Russian He ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30581-8&doi=10.1016/j.jval.2017.08.247
First page :
A441
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
224